Amgen said on Monday its experimental therapy helped patients with advanced gastric cancer live longer when combined with ...

The Dow Dow Jones Industrial Average was most recently trading 492 points higher (1.1%), as shares of Amgen Amgen Inc. and Merck Merck & Co. Inc. have contributed around 25% of the blue-chip gauge's ...

Buoyed by positive gains for shares of Amgen and Merck, the Dow Jones Industrial Average is climbing Tuesday morning. Shares of Amgen and Merck are contributing to the blue-chip gauge's intraday rally ...

Amgen acquired Five Prime in 2021 on the back of the phase 2 FIGHT trial of bemarituzumab, which achieved significant ...

Amgen plans to proceed with Phase 3 trials, initiating patients on a lower dosage that will gradually increase over an ...

In a detail-thin announcement, Amgen said that adding bemarituzumab to chemotherapy improved overall survival, though ...

Amgen's Phase 3 trial of bemarituzumab plus chemo met its survival goal in FGFR2b+ gastric cancer, with full data expected ...

Back in 2021, Amgen picked up the phase 3-ready candidate in a $1.9 billion acquisition of Five Prime Therapeutics. The ...

THOUSAND OAKS, Calif., June 30, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the Phase 3 FORTITUDE-101 clinical trial evaluating first-line bemarituzumab plus chemotherapy (mFOLFOX6) met ...

Amgen’s monthly obesity candidate led to substantial weight loss but a high rate of side effects and discontinuations in a ...

Amgen said a Phase 3 trial of its gastric cancer treatment, bemarituzumab, met its primary endpoint of overall survival at a pre-specified interim analysis.

Amgen's long-acting experimental obesity drug MariTide needs to be given at a low starting dose to limit side effects like ...